Livzon Pharmaceutical Group Inc. [000513.SZ] Stock Forecast

Livzon Pharmaceutical Group Inc. engages in the research, development, production, and sale of pharmaceutical products, and active pharmaceutical ingredients and intermediates in the People's Republic of China. The company offers Ilaprazole enteric coated tablets for the treatment of duodenal ulcers and reflux esophagitis; Laprazole sodium for injection to treat peptic ulcer hemorrhage; Leuprorelin Acetate Microspheres for injection; Urofollitropin for injection to treat anovulation and sufferers; Perospirone Hydrochloride for the treatment of schizophrenia; Anti-viral Granules to treat upper respiratory tract infection and influenza; and Shenqi Fuzheng Injection for the treatment of weakness and tiredness, lassitude, spontaneous sweating, and vertigo, as well as for the patients of lung and stomach cancer. It also offers diagnostic reagents, such as diagnostic kit for IgM/IgG antibody to coronavirus; nucleic acid test kit for human immunodeficiency virus type 1; antinuclear antibody test kits; interferon-gamma release assays test kits; and rapid test for mycoplasma pneumoniae IgM antibody. In addition, the company provides biochemical drugs, microbiological preparations, biologic products, Chinese drug preparations and pharmaceutical raw materials, and antibiotics. It also exports its products. The company was founded in 1985 and is headquartered in Zhuhai, China.